IL1B and cardiovascular disorder: IL-1β is an important proatherogenic factor, and a recent study revealed that targeting IL-1β using an IL-1β-neutralizing antibody has proven beneficial for cardiovascular diseases in the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) trial [8].